ResMed Inc.

RMD Healthcare Medical Instruments & Supplies

ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025.

Revenue
+5.93%
EPS
+23.1%
Free cash flow
−9.79%
Total debt
−38.9%

Quarter to September 2026, against a year earlier

238.80 1.71 −0.71%
Market cap
$33.7B
P/E
21.7×
Fwd P/E
19.6×
Dividend yield
1.03%
F-score
6/9
Altman Z
10.00
Beneish M
−2.59
Dividend safety
96/100
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
20.08 18.63 21.58 23.73

+8 more quarters

P/S ratio
5.51 5.02 5.89 6.51
P/FCF ratio
19.90 17.41 18.79 19.77
P/Operating CF
74.84 62.38 58.88 103.40
P/B ratio
5.32 4.31 5.03 5.56
EV/Sales
5.38 4.83 5.66 6.32
EV/EBITDA
14.48 12.81 14.55 16.52
EV/FCF
19.42 16.76 18.07 19.20
Current Ratio
2.65 3.10 3.01 3.06
Net Debt/EBITDA
(1.51) (2.12) (2.21) (1.83)
Debt/Equity
0.04 0.06 0.06 0.06
Earnings Yield
4.98% 5.37% 4.63% 4.21%
Free Cash Flow Yield
5.02% 5.74% 5.32% 5.06%
Free Cash Flow per Share
2.60 2.73 3.54 2.09
Book value per Share
41.60 45.25 44.67 43.34
Free Cash Flow
371.25 397.38 514.54 305.19
EV/EBIT
16.30 14.46 16.58 18.76
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026